Besides endogenous ligands such as oxLDL, exogenous PPAR-γ ligands, including the thioglitazone class of drugs, also upregulate CD36 (Ballesteros et al., 2014; Kolak et al., 2007), perhaps contributing to the increase in cardiovascular risk associated with their use in patients with type 2 diabetes. Here, CD36 is linked to type 2 diabetes mellitus.